Chinese oncology drug developer Tot Biopharm raises $75.2m in HK IPO

Photo by Louis Reed on Unsplash

Tot Biopharm, a Chinese clinical-stage biopharma firm specialized in innovative oncology drugs and therapies, has raised about $75.2 million in an initial public offering (IPO) on the main board of the Hong Kong stock exchange on Friday.

The biopharma company offered 90 million shares at a price of HK$6.55 apiece, the lower end of the proposed price range between HK$7.55 and HK$6.55.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter